Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (DE:CN2)
FRANKFURT:CN2
Earnings Data
Report Date
Mar 18, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.26Last Year’s EPS
0.38Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Q3 2025
Earnings Call Date:Nov 05, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted Catalyst Pharmaceuticals' strong financial performance, driven by significant growth in FIRDAPSE and AGAMREE, as well as the company's solid cash position and raised revenue guidance. However, the decline in FYCOMPA revenue due to generic competition and ongoing patent litigation for FIRDAPSE were noted challenges.Company Guidance
Record Revenue Growth
Catalyst Pharmaceuticals reported a record quarter in Q3 2025 with total revenue reaching $148.4 million, an increase of 15.3% year-over-year.
Strong FIRDAPSE Performance
FIRDAPSE generated revenue of $92.2 million, marking a 16.2% increase year-over-year, maintaining its position as the only evidence-based approved product in the U.S. for the treatment of Lambert-Eaton myasthenic syndrome.
AGAMREE's Significant Growth
AGAMREE generated $32.4 million in net product revenue in Q3 2025, a 115.2% increase year-over-year from Q3 2024, driven by a strong 90% patient retention rate and growing adoption across DMD centers.
Solid Financial Position
Catalyst ended the third quarter of 2025 with a cash position of $689.9 million and no debt, reinforcing its ability to invest strategically for long-term growth.
Raised Revenue Guidance
Catalyst raised its 2025 total revenue guidance to between $565 million and $585 million, reflecting confidence in continued strong performance.
DE:CN2 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:CN2 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 05, 2025 | €18.32 | €19.98 | +9.09% |
Aug 06, 2025 | €18.98 | €16.98 | -10.56% |
May 07, 2025 | €20.11 | €20.68 | +2.83% |
Feb 26, 2025 | €19.41 | €21.47 | +10.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Catalyst Pharma (DE:CN2) report earnings?
Catalyst Pharma (DE:CN2) is schdueled to report earning on Mar 18, 2026, After Close (Confirmed).
What is Catalyst Pharma (DE:CN2) earnings time?
Catalyst Pharma (DE:CN2) earnings time is at Mar 18, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Catalyst Pharma stock?
The P/E ratio of Catalyst Pharma is N/A.
What is DE:CN2 EPS forecast?
DE:CN2 EPS forecast for the fiscal quarter 2025 (Q4) is 0.26.